Carrie A. Schinstock, M.D., is a clinical and translational researcher focused on improving care for patients receiving kidney transplants. She is particularly interested in developing a therapy for chronic antibody-mediated rejection that leads to allograft failure.
- Donor-specific antibody characterization. Dr. Schinstock and colleagues are focused on characterizing donor-specific antibodies that attack the human leukocyte antigen (anti-HLA antibodies) in patients receiving renal transplants. They then draw connections between antibody characterization and patient outcomes, with the goal of determining whether certain characteristics are tied to transplant failure.
- Antibody assessment. Additionally, Dr. Schinstock and collaborators are working to develop a new method for assessing how donor-specific antibodies affect transplanted organs. They are adapting laser capture microdissection techniques, used together with gene expression studies, to better understand the effects of donor-specific antibodies in kidney transplantation.
Significance to patient care
As a clinical and translational researcher, Dr. Schinstock is working to better understand the processes of kidney disease and kidney transplantation with the goal of applying her findings to best serve patients in the clinical setting.
- Scholar, KL2 Mentored Career Development Program, funded by the National Institutes of Health and the Center for Clinical and Translational Science, Mayo Clinic, 2015-2018
- Mayo Clinic Quality Fellow, Bronze Certification, 2014
- Recipient, Outstanding Achievement Award for top fellow of graduating class, Nephrology Fellowship, Mayo School of Graduate Medical Education, 2008